Sun Pharmaceutical Industries Ltd to Raise ₹10,000 Crore

Sun Pharmaceutical Industries is in focus after reports on October 21, 2026, indicated that the company is raising ₹10,000 crore through rupee-denominated bonds to partially finance its acquisition of Organon & Co. The fundraising is expected to be carried out in two tranches, with coupon rates of 8.05% and 8.20%, respectively. The move forms part of the company’s financing strategy for the major overseas acquisition. The proposed fundraising follows Sun Pharma’s earlier plan to raise funds through non-convertible debentures (NCDs) to support the Organon transaction. The acquisition is a significant strategic step aimed at expanding Sun Pharma’s global presence and strengthening its portfolio across branded medicines and specialty healthcare. Investors will closely track the funding structure and the company’s ability to manage the additional debt efficiently. Going forward, market participants will monitor the acquisition’s progress, financing costs and potential contribution to long-term revenue growth. Sun Pharma has also scheduled the announcement of its Q2 FY27 financial results for October 30, 2026. The results, along with updates on the Organon acquisition, will be key triggers for investor sentiment and the stock’s performance.